Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume 28, Issue 10, Pages 3324-3331Publisher
WILEY
DOI: 10.1111/ene.14703
Keywords
COVID-19; GFAp; NfL; SARS-CoV-2; total tau
Categories
Funding
- Swedish Research Council [2017-00915, 2014-02569, 2014-07606]
- Open Medicine Foundation
- SciLife/KWA
- Swedish Society of Medicine
- Swedish Society for Medical Research
- Swedish government [ALFGBG-715986]
- Swedish County Councils, and the ALF [ALFGBG-715986]
- Swedish Research Council [2014-07606] Funding Source: Swedish Research Council
Ask authors/readers for more resources
This study analyzed CSF biomarkers of CNS injury in 19 patients with neurological symptoms of COVID-19, finding elevated levels of NfL protein, GFAp, and total tau. NfL protein was found to be associated with central neurological symptoms and disease severity in these patients.
Background and purpose: Neurological symptoms have been frequently reported in hospitalized patients with coronavirus disease 2019 (COVID-19), and biomarkers of central nervous system (CNS) injury are reported to be increased in plasma but not extensively studied in cerebrospinal fluid (CSF). This study examined CSF for biomarkers of CNS injury and other pathology in relation to neurological symptoms and disease severity in patients with neurological manifestations of COVID-19. Methods: Nineteen patients with neurological symptoms and mild to critical COVID-19 were prospectively included. Extensive analysis of CSF, including measurement of biomarkers of CNS injury (neurofilament light chain [NfL] protein, glial fibrillary acidic protein [GFAp], and total tau), was performed and compared to neurological features and disease severity. Results: Neurological symptoms included altered mental status (42%), headache (42%), and central (21%) and peripheral weakness (32%). Two patients demonstrated minor pleocytosis, and four patients had increased immunoglobulin G levels in CSF. Neuronal autoantibody testing using commercial tests was negative in all patients. Increased CSF levels of NfL protein, total tau, and GFAp were seen in 63%, 37%, and 16% of patients, respectively. Increased NfL protein correlated with disease severity, time in intensive care, and level of consciousness. NfL protein in CSF was higher in patients with central neurological symptoms. Conclusions: Although limited by the small sample size, our data suggest that levels of NfL protein, GFAp, and total tau in CSF are commonly elevated in patients with COVID-19 with neurological symptoms. This is in contrast to the standard CSF workup where pathological findings are scarce. NfL protein, in particular, is associated with central neurological symptoms and disease severity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available